A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

  • STATUS
    Recruiting
  • End date
    Apr 1, 2027
  • participants needed
    53
  • sponsor
    Naoyuki G. Saito, M.D., Ph.D.
Updated on 16 June 2022
remission
myeloid leukemia
fludarabine
myelodysplasia
ejection fraction
cell transplantation
myeloablative conditioning
leukemia
transplant conditioning
blast cells
TP53
basophils

Summary

This is a phase I/II clinical trial to determine the maximum tolerated dose (MTD) of total marrow irradiation (TMI) followed by fludarabine in the context of a myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as well as to determine the efficacy of the regimen in patients with high-risk leukemia and myelodysplasia.

Description

This is a phase I/II clinical trial to determine the maximum tolerated dose (MTD) of total marrow irradiation (TMI) followed by fludarabine in the context of a myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as well as to determine the efficacy of the regimen in patients with high-risk leukemia and myelodysplasia. TMI, which allows for conformal dosing of target bone marrow tissue while giving lower doses to organs at risk, is considered by many to be a superior alternative to conventional total body irradiation (TBI). Through the use of TMI, it is possible to escalate the dose of radiation to the bone marrow while keeping the dose to normal organs at acceptable levels, effectively widening the therapeutic window of this modality. This conditioning regimen will be tried in patients with relapsed or refractory hematologic malignancies.

Primary Objectives:

Phase I: Determine the MTD of TMI (delivered twice a day for 5 days) followed by fludarabine (fixed at 150 mg/m2 given over 5 days) as a conditioning regimen for Allo-HSCT for patients with high risk (relapsed/refractory) acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelogenous leukemia (CML).

Phase II: Single-arm exploratory study to expand the cohort at the MTD level to estimate 1- year overall survival (OS), with the objective of increasing the OS from the historical rate of 30% (null hypothesis) to 50% (alternate hypothesis) with 80% power and a one-sided type I error of 0.05.

Secondary Objectives

  1. Describe the extramedullary toxicity and the incidence of complications, including mucositis, acute and chronic graft versus host disease (GvHD), sinusoidal obstruction syndrome (SOS), and pneumonitis.
  2. Describe the time to engraftment of neutrophils and platelets
  3. Describe the disease response rate at Day 30 after transplantation
  4. Describe the overall survival and disease-free survival
  5. Describe the cumulative incidence of relapse and non-relapse mortality 6
  6. Determine the correlation between plasma/serum markers and radiation induced acute and long term toxicities.
  7. Describe the quality of life metrics of participating subjects

Details
Condition Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
Treatment Fludarabine + Total Marrow Irradiation
Clinical Study IdentifierNCT05201183
SponsorNaoyuki G. Saito, M.D., Ph.D.
Last Modified on16 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Documentation of Disease: Patients must be diagnosed with one of the following
conditions
Acute Myeloid Leukemia (AML), with no history of extramedullary disease, who are not in complete remission, who have either primary refractory or relapsed disease, and who do not have more than one of the following adverse factors
Duration of first CR < 6 months (if previously in CR), based on the best overall clinical assessment of the disease course, not solely based on blood test or bone marrow biopsy results
Poor risk karyotype including any of the following: complex karyotype with ≥3 clonal abnormalities, 5q-/-5, 7q-/-7, 11q23 abnormalities, inv(3q), 20q or 21q abnormalities, t (6;9), t (9;22), 17p abnormalities [or TP53 mutations] or monosomal karyotype. Molecular typing (except for TP53 mutation) will not be used for eligibility criteria determination
Circulating peripheral blood blasts at time of enrollment
Acute Lymphocytic Leukemia (ALL) who are not in complete remission, who have
either primary refractory or relapsed disease, and who do not have more than
one of the following adverse factors
Primary refractory or first relapse. Patients in second or subsequent relapse are excluded
Bone marrow blasts >25% within 30 days before the start of the conditioning regimen
Age >40 years
Myelodysplasia with a Revised International Prognostic Score (IPSS-R) of greater
than 4.5 (i.e., high- or very-high risk)
Chronic Myelogenous Leukemia (CML) in accelerated phase, defined by any of the
following
-19% blasts in peripheral blood white cells or bone marrow
Peripheral blood basophils at least 20%
Persistent thrombocytopenia (< 100 x 109/l) unrelated to therapy, or persistent thrombocytosis (>1000 x 109/l) unresponsive to therapy
Increasing spleen size and increasing white blood cell (WBC) count unresponsive to therapy
Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase)
The patient must be 18-65 years old at time of consent
Signed written informed consent: Patient must be capable of understanding the investigational nature of this study, potential risks and benefits of the study, and be able to provide a valid informed consent
Availability of a consenting human leukocyte antigens (HLA)-matched donor
Karnofsky Performance Status 70% or higher
Required baseline laboratory values
Estimated creatinine clearance ≥ 60 ml/min
Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal value
Bilirubin ≤ 1.5 x upper limit of normal value (unless determined to be related to Gilbert's disease)
Required baseline cardiac function values
Required baseline cardiac function of left ventricular ejection fraction (LVEF) > 45 % corrected
Required baseline pulmonary function values
Required baseline pulmonary function of lung diffusing capacity (DLCO) > 45 % predicted (corrected for hemoglobin))

Exclusion Criteria

HIV seropositive patients
Pregnant or nursing females
Prior radiation therapy
Patients who have had a prior autologous or allogeneic bone marrow or stem cell transplantation
Gemtuzumab ozogamicin (trade name: Mylotarg) and/or inotuzumab ozogamicin (trade name: Besponsa) use within 60 days before start of the conditioning regimen
Though this is NOT an exclusion criterion, we strongly recommend discontinuation of any steroidal oral contraceptives at least 7 days before start of the conditioning regimen. Use of therapeutic alternatives, including leuprolide should be considered to reduce the risk of SOS/VOD. Of note, for patients already on steroidal oral contraceptives for excessive menorrhagia, the switch to leuprolide should occur at least 2 weeks before the start of the conditioning regimen
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note